New combo therapy tested for Tough-to-Treat breast cancer
NCT ID NCT05530057
Summary
This study is for people with advanced HER2-positive breast cancer that has worsened despite at least two prior standard HER2-targeted treatments. Researchers want to see if adding a drug called trastuzumab (a HER2-targeted therapy) to a chemotherapy drug called eribulin works better than eribulin alone to control the cancer. The main goal is to see which approach keeps the cancer from growing for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
Contact
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.